These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12806959)

  • 1. [Hematopoietic stem cell transplant in cancer treatment].
    Masaoka T
    Nihon Rinsho; 2003 Jun; 61(6):1052-5. PubMed ID: 12806959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematopoietic stem cell transplantation: current status.
    Kumar L
    Natl Med J India; 2007; 20(3):128-37. PubMed ID: 17867617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
    Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products.
    Gratwohl A; Baldomero H; Frauendorfer K; Rocha V; Apperley J; Niederwieser D; ;
    Bone Marrow Transplant; 2008 Apr; 41(8):687-705. PubMed ID: 18084334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003.
    Gratwohl A; Baldomero H; Schmid O; Horisberger B; Bargetzi M; Urbano-Ispizua A
    Bone Marrow Transplant; 2005 Oct; 36(7):575-90. PubMed ID: 16086045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the toxicity of hematopoietic stem cell transplant.
    Pallera AM; Schwartzberg LS
    J Support Oncol; 2004; 2(3):223-37; discussion 237-8, 241, 246-7. PubMed ID: 15328824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.
    Jacobsohn DA; Hewlett B; Ranalli M; Seshadri R; Duerst R; Kletzel M
    Bone Marrow Transplant; 2004 Nov; 34(10):901-7. PubMed ID: 15361908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey.
    Gratwohl A; Baldomero H; Passweg J; Urbano-Ispizua A;
    Bone Marrow Transplant; 2002 Dec; 30(12):813-31. PubMed ID: 12476273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A; Passweg J; Baldomero H; Hermans J
    Bone Marrow Transplant; 1998 Aug; 22(3):227-40. PubMed ID: 9720735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
    Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
    Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
    Cheng YC; Ueno NT
    Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.
    Wingard JR; Hsu J; Hiemenz JW
    Infect Dis Clin North Am; 2010 Jun; 24(2):257-72. PubMed ID: 20466269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBMT activity survey 2004 and changes in disease indication over the past 15 years.
    Gratwohl A; Baldomero H; Frauendorfer K; Urbano-Ispizua A; ;
    Bone Marrow Transplant; 2006 Jun; 37(12):1069-85. PubMed ID: 16757972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.